Avaxia Biologics Secures $2,200,000 Series A Financing Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=627cd2c1-d962-4b66-bfa9-cead3a68e96a&Preview=1 -
Date
11/10/2011 -
Company Name
Avaxia Biologics -
Mailing Address
128 Spring Street Lexington, MA 02421 -
Company Description
Avaxia is developing oral antibody products for diseases and disease targets that can be reached through the mouth and the gastrointestinal tract. -
Website
http://www.avaxiabiologics.com -
Transaction Type
Venture Equity -
Transaction Amount
$2,200,000 -
Transaction Round
Series A -
Proceeds Purposes
This investment will allow us to aggressively pursue the development of our AVX-470 anti-TNF oral antibody and prepare Avaxia to initiate a clinical trial in inflammatory bowel disease next fall. -
M&A Terms
-
Venture Investor
Cherrystone Angel Group -
Venture Investor
Boston Harbor Angels -
Venture Investor
Undisclosed
